Wow!
It matters not to PER
Why?
1) Boys that can access the gene therapy drug will get it
others will use other therapies..
2)The cost $3.2 million will be a stumbling block
3) US clinicians are skeptical re efficacy
4)Sarepta is yet to make a profit from the other exon skipping drug
5)Gene therapy has still got a long way to go before it’s widely accepted
6) All in all PER will continue with its path forward
Other exon skipping drugs will use combination therapies.. eg Atl1102
.
https://finance.yahoo.com/news/sarepta-therapeutics-announces-expanded-us-210200030.html
- Forums
- ASX - By Stock
- PER
- FDA approves Sareptas Srp901 for the whole population
FDA approves Sareptas Srp901 for the whole population
-
- There are more pages in this discussion • 63 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
MND
Albemarle lithium downsize burns $200M hole in Monadelphous's pocket as latter's contracts terminated
AVH
Avita boosts skin restoration product portfolio with 'dermal matrix' – a kind of next-level gauze made of fake skin
Add PER (ASX) to my watchlist
|
|||||
Last
7.0¢ |
Change
-0.001(1.41%) |
Mkt cap ! $63.10M |
Open | High | Low | Value | Volume |
7.1¢ | 7.1¢ | 6.9¢ | $34.01K | 486.5K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 132919 | 6.9¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
7.3¢ | 78000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 80000 | 0.069 |
4 | 134427 | 0.068 |
3 | 224490 | 0.067 |
1 | 15000 | 0.066 |
4 | 32000 | 0.065 |
Price($) | Vol. | No. |
---|---|---|
0.073 | 78000 | 1 |
0.075 | 13371 | 1 |
0.078 | 75476 | 2 |
0.079 | 175123 | 2 |
0.080 | 287231 | 3 |
Last trade - 16.10pm 02/08/2024 (20 minute delay) ? |
Featured News
MND
Albemarle lithium downsize burns $200M hole in Monadelphous's pocket as latter's contracts terminated
KAI
Pilbara Minerals buys land off Kairos part of its York gold project for $20M – and a 2% royalty on any PLS gold sales
PER (ASX) Chart |